News

The FDA has granted a priority review to a supplemental new drug application for crizotinib in the treatment of pediatric patients with ALK-positive relapsed/refractory systemic anaplastic large cell lymphoma.

Igor Puzanov, MD, MSCI, FACP, has been promoted to Senior VP of Clinical Investigation and will grow Center for Early-Phase Clinical Trials.

OncLive®, the nation’s leading multimedia resource focused on providing oncology professionals with relevant, insightful information on patient care, is pleased to announce the Eighth Annual Giants of Cancer Care® class of inductees.

Hemigland high-intensity focused ultrasound ablation of the prostate was found to be a safe and effective primary treatment for men with localized prostate cancer, leading to continence preservation and suitable short-term disease control.

Rafael F. Duarte, MD, PhD, FRCP, presents 2 real-world clinical cases in which the investigational monoclonal antibody narsoplimab demonstrated clinical benefit in patients with hematopoietic stem cell transplantation-associated thrombotic microangiopathy.

Tipifarnib demonstrated encouraging antitumor activity in patients with recurrent and metastatic head and neck cancer with high HRAS-mutant variant allele frequency, surpassing historical competitors in the second- or later-line settings.

The interim futility review for the phase 2 HopES Sarcoma trial was positive and will continue to evaluate SM-88 for patients with Ewing sarcoma and other high-risk sarcomas.

Patients with a suspected or diagnosed myeloproliferative neoplasm should undergo targeted next-generation sequencing versus sequential or allele specific testing to reduce the risk of identifying a false driver mutation or an excluded diagnosis of MPN.

Georgina V. Long, BSc, PhD, MBBS, FRACP, discusses the safety profile of the combination of spartalizumab, dabrafenib, and trametinib, the clinical implications of the biomarker data observed from this trial, and other emerging combinations on the horizon.

Paul L. Nguyen, MD, discusses the role of radiation in high-risk prostate cancer and ongoing research efforts in the space.

Vamsidhar Velcheti, MD, discusses the current and emerging treatment options for patients with ALK- and ROS1-positive non–small cell lung cancer.

Heinz-Josef Lenz, MD, FACP, discusses third-line treatment approaches that are generating excitement in colorectal cancer.

Any type of anti-cancer therapy that could impact overall survival should not be discontinued or delayed.

Michael Wang, MD, discusses the FDA approval of brexucabtagene autoleucel in mantle cell lymphoma and ongoing research aimed at optimizing the safety and persistence of the product.

The FDA has granted a breakthrough therapy designation to osimertinib for the adjuvant treatment of patients with stage IB, II, and IIIA EGFR-mutated non–small cell lung cancer following complete resection with curative intent.

The administration of luteinizing hormone-releasing hormone agonists in patients with prostate cancer was significantly more delayed in clinical practice than in pivotal clinical trials.

Pembrolizumab was found to prolong survival in patients with advanced melanoma, regardless of BRAF V600E/K mutation status or prior administration of a BRAF inhibitor with or without a MEK inhibitor.

Lori A. Leslie, MD, discusses the current treatment landscape in mantle cell lymphoma, factors to consider when selecting between BTK inhibitors, and other treatment options on the horizon.

Noopur S. Raje, MD, discusses some of the most noteworthy research presented at the 2020 ASCO Virtual Scientific Program and the 2020 European Hematology Association Congress in multiple myeloma.

Treatment with immune checkpoint inhibitors did not increase the risk of mortality in patients with COVID-19 and cancer.

Tanios S. Bekaii-Saab, MD, FACP, discusses the rapidly changing hepatocellular carcinoma treatment landscape and shares advice on how he navigates among the available options available for these patients.

A new FDA program is giving patients and providers first-time access to patient-reported outcome data from cancer clinical trials of marketed treatments.

The combination of pepinemab and avelumab was found to be well tolerated and demonstrated initial signals of antitumor activity in patients with advanced stage, non–small cell lung cancer.

Separate studies identify survivin as possible therapeutic target and report encouraging benefits from nintedanib.

Liquid biopsy with circulating tumor DNA could help alleviate some of the challenges of tissue biopsy in prostate cancer, and in doing so, lead to a better precision medicine model in the field.